Case Report on Rare FGFR2 Fusion in Ovarian Cancer
Author Information
Author(s): Sono Reiri, Konecny Gottfried E., Zhang Liying
Primary Institution: David Geffen School of Medicine, University of California, Los Angeles
Hypothesis
Can FGFR2::IQCG fusion in high-grade serous tubo-ovarian carcinoma provide insights into targeted therapy?
Conclusion
The study presents a rare case of FGFR2::IQCG fusion in ovarian cancer, highlighting challenges in predicting therapy efficacy.
Supporting Evidence
- FGFR2 fusions are common in some cancers but rare in ovarian adenocarcinomas.
- The patient had multiple relapses and underwent various lines of therapy.
- The FGFR2::IQCG fusion was identified in tumors from both the initial and sixth relapses.
Takeaway
This study talks about a woman with a rare type of ovarian cancer that had a special gene fusion, which made it hard to treat her effectively.
Methodology
Clinical history, histopathology results, and molecular pathology results were retrieved from the electronic health record system.
Limitations
The unavailability of pre-therapeutic molecular study limits the interpretation of the FGFR2 fusion's role in primary chemoresistance.
Participant Demographics
The patient is a 62-year-old woman.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website